Home About Clinicians Patients Investors Careers Media Contact Clinicians > Ongoing Clinical Studies Click here for further information on ongoing studies with SIR-Spheres® Y-90 resin microspheres on www.clinicaltrials.gov Liver Metastases Title Setting Sponsor Study ID Treatment Arm(s) N Location TAS-102 and radioembolisation with SIR-Spheres Y-90 resin microspheres for chemorefractory colorectal liver metastases Chemorefractory mCRC Investigator initiated study NCT02602327 TAS 102 + SIR-Spheres Y-90 resin microspheres 24 USA SIRUM SIR-Spheres Y-90 resin microspheres treatment of uveal melanoma metastasised to liver Uveal melanoma liver metastasis Investigator initiated study NCT01473004 SIR-Spheres Y-90 resin microspheres 48 USA SIRTAC SIR-Spheres Y-90 resin microspheres vs. TACE treatment of uveal melanoma metastazised to liver Uveal melanoma liver metastasis Investigator initiated study NCT02936388 SIR-Spheres Y-90 resin microspheres vs. TACE (cisplatin+embocept) 108 Germany A feasibility study of sequential hepatic internal radiation and systemic ipilimumab and nivolumab in patients with uveal melanoma metastatic to liver Uveal melanoma liver metastasis Investigator initiated study NCT02913417 Sequential SIR-Spheres Y-90 resin microspheres > ipilimumab + nivolumab > nivolumab 18 USA Primary Liver Cancer Title Setting Sponsor Study ID Treatment Arm(s) N Location Study of Y-90 radioembolisation with nivolumab in Asians with hepatocellular carcinoma Hepatocellular carcinoma Investigator initiated study NCT03033446 SIR-Spheres Y-90 resin microspheres > nivolumab 40 Singapore NASIR-HCC A study of the safety and antitumoral efficacy of nivolumab after SIRT for the treatment of patients with HCC Hepatocellular carcinoma Investigator initiated study NCT03380130 SIR-Spheres Y-90 resin microspheres > nivolumab 40 Spain SIRCCA SIRT followed by CIS-GEM chemotherapy versus CIS-GEM chemotherapy alone as 1st line treatment of patients with unresectable intrahepatic cholangiocarcinoma Intrahepatic cholangiocarcinoma Sirtex NCT02807181 SIR-Spheres Y-90 resin microspheres > cisplatin + gemcitabine vs. cisplatin + gemcitabine 180 Global STOCS This study aims to study the benefits of sequential administration of SIRT followed by standard chemotherapy for treatment of inoperable intrahepatic cholangiocarcinoma Intrahepatic cholangiocarcinoma Investigator initiated study NCT02167711 SIR-Spheres Y-90 resin microspheres > gemcitabine + cisplatin 24 Hong Kong Singapore Thailand MIRD Current experience on yttrium-90 radioembolisation utilising resin microspheres with MIRD-model dosimetry Intrahepatic cholangiocarcinoma and Hepatocellular carcinoma with portal vein invasion Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres 25 USA Liver Metastases and Primary Liver Cancer Title Setting Sponsor Study ID Treatment Arm(s) N Location AROMA Abscopal effects after radioembolisation of metastatic colorectal cancer mCRC, HCC, mBC Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres 60 Germany Registries Title Setting Sponsor Study ID Treatment Arm(s) N Location CIRT CIRSE registry for SIR-Spheres therapy Primary and secondary liver tumors CIRSE NCT02305459 SIR-Spheres Y-90 resin microspheres >1050 Europe CIRT-FR CIRSE registry for SIR-Spheres therapy in France Primary and secondary liver tumors CIRSE NCT03256994 SIR-Spheres Y-90 resin microspheres 200 France RESIN (USA) Yttrium Y-90 resin microspheres data collection in unresectable liver cancer: the RESIN study Primary and secondary liver tumors Investigator initiated study NCT02685631 SIR-Spheres Y-90 resin microspheres 3000 USA ESSURE European SIR-Spheres Surgical Registry Primary and secondary liver tumors Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres 250 Germany BSIR SIRT Registry British Society of Interventional Radiology Primary and secondary liver tumors Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres UK Registry of selective internal radiation therapy in Vietnam Hepatocellular carcinoma Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres 30 Vietnam RESIN (Taiwan) REgistry of Selective Internal radiation therapy in TaiwaN Hepatocellular carcinoma Investigator initiated study NCT03292991 SIR-Spheres Y-90 resin microspheres 100 Taiwan, Singapore, Thailand RESiN (ANZ) Radiation-Emitting SIR-Spheres in Non-resectable Liver Tumor Primary and secondary liver tumors Investigator initiated study not registered SIR-Spheres Y-90 resin microspheres >150 Australia and New Zealand DOORwaY-90 Study International Recommendations FLEXdose Delivery Programme About SIRT About SIR-Spheres microspheres + mCRC Clinical Studies + HCC Clinical Studies + Ongoing Clinical Studies Customer Support and Training Programs Events Frequently Asked Questions Who we are Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. What are SIR-Spheres® Y-90 resin microspheres? SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. To view the Technical Bulletin regarding our indication, click here. Contact or follow us Contact Us SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Terms of Use | Privacy Information 098-EUA-0219